1226 / 1578
Trageted Therapy: Described Side effects
Sperduto PW Phase III trial (RTOG
0320)
WBRT/SRT
Temozolamid
Erlotinib
47% grade ¾
Skin reaction
including acne
Pneumonia
Muscle weakness
Myocardial ischemia
Brain necrosis
Schulze B
Case reports
WBRT
BRAF inhibitor
Vermurafenib
Skin toxicity
Kies AP
SRS
Ipilimumab
Symptomatic
Radionecrosis
•
Targeted therapy in combination with RT can increase side effects
•
Targeted therapy may have a radiosensitizing effect
•
Studies have to be performed evaluating side effects